$20.97
-5.9%Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Strong working capital position provides significant operational flexibility and financial cushion.
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
UPB • NASDAQ
| Upstream Bio, Inc. Balance Sheet | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|
ASSETS | |||
CURRENT ASSETS | |||
325.9M | 25.8M | 17.1M | |
144.6M | 84M | 0.0 | |
470.5M | 109.8M | 17.1M | |
1.2M | 236K | 412K | |
613K | 98K | 412K | |
567K | 138K | 0.0 | |
7M | 6.6M | 611K | |
494K | 370K | 233K | |
479.2M | 117M | 18.3M | |
NON-CURRENT ASSETS | |||
2.4M | 202K | 164K | |
194K | 0.0 | 7K | |
2.6M | 202K | 171K | |
481.7M | 117.2M | 18.5M | |
LIABILITIES | |||
CURRENT LIABILITIES | |||
4M | 2M | 712K | |
4M | 2M | 712K | |
3.3M | 2.3M | 3.2M | |
704K | 45K | 87K | |
704K | 45K | 87K | |
2M | 2.1M | 806K | |
10.7M | 6.5M | 4.9M | |
NON-CURRENT LIABILITIES | |||
0.0 | 2.9M | 6.9M | |
1.1M | 233.8M | 119.8M | |
1.8M | 45K | 94K | |
11.9M | 240.3M | 124.6M | |
SHAREHOLDERS' EQUITY | |||
0.0 | 230.9M | 112.8M | |
53K | 3K | 3K | |
660.6M | 4.8M | 1.3M | |
-190.8M | -128M | -107.4M | |
-25K | 21K | 0.0 | |
469.9M | -123.1M | -106.2M | |
469.9M | -123.1M | -106.2M | |
SUMMARY | |||
481.7M | 117.2M | 18.5M | |
144.6M | 84M | 0.0 | |
1.8M | 45K | 94K | |
-324.1M | -25.8M | -17M | |
53,909,427 | 53,909,427 | 53,909,427 |
UPB - Filing history and reports
No SEC filings available for UPB
Continue your UPB research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.